AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A method of inhibiting cytotoxic response of a T lymphocyte in a mammalian subject, said method comprising:

a) determining said mammalian subject has a condition characterized by ~~associated with abnormal generation or function of~~ elevated CTL activity by assaying said activity; and

b) administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof that binds PSGL.

2-25. (Canceled)

26. (Previously presented) The method of claim 1, wherein said antibody is chosen from a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, and a humanized antibody, or fragments thereof that bind PSGL.

27. (Previously presented) The method of claim 1, wherein said antibody is administered in a pharmaceutically acceptable formulation.

28. (Currently amended) A method for treating or ameliorating a disease or condition resulting from a cytotoxic response of a T lymphocyte comprising:

a) determining said mammalian subject has a condition characterized by ~~associated with abnormal generation or function of~~ elevated CTL activity by assaying said activity; and

b) administering to said subject a therapeutically effective amount of an antibody directed to P-selectin glycoprotein ligand (PSGL), or a fragment thereof that binds PSGL.

29. (Previously presented) The method of claim 28, wherein said disease or condition is an autoimmune condition.

30. (Withdrawn) The method of claim 28, wherein said disease or condition is an allergic reaction.

31. (Withdrawn) The method of claim 28, wherein said disease or condition is asthma.

32. (Previously presented) The method of claim 28, wherein said antibody is a monoclonal antibody, or a fragment thereof that binds PSGL.

33. (Canceled)

34. (Previously presented) The method of claim 28, wherein said antibody is administered in a pharmaceutically acceptable formulation.

35. (Canceled)

36. (New) The method of claim 1, wherein said CTL activity is assayed in peritoneal exudate lymphocytes.

37. (New) The method of claim 28, wherein said CTL activity is assayed in peritoneal exudate lymphocytes.